## Aurélien Latouche

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/2020806/publications.pdf

Version: 2024-02-01

46 papers

2,165 citations

279798 23 h-index 276875 41 g-index

46 all docs

46 docs citations

46 times ranked

3996 citing authors

#	Article	IF	Citations
1	A parametric approach to relaxing the independence assumption in relative survival analysis. International Journal of Biostatistics, 2022, 18, 577-592.	0.7	1
2	Insights for Quantifying the Long-Term Benefit of Immunotherapy Using Quantile Regression. JCO Precision Oncology, 2021, 5, 173-176.	3.0	2
3	Total metabolic tumor volume and spleen metabolism on baseline [18F]-FDG PET/CT as independent prognostic biomarkers of recurrence in resected breast cancer. European Journal of Nuclear Medicine and Molecular Imaging, 2021, 48, 3560-3570.	6.4	14
4	Circulating HPV DNA as a Marker for Early Detection of Relapse in Patients with Cervical Cancer. Clinical Cancer Research, 2021, 27, 5869-5877.	7.0	36
5	A review of the use of timeâ€varying covariates in the Fineâ€Gray subdistribution hazard competing risk regression model. Statistics in Medicine, 2020, 39, 103-113.	1.6	70
6	On evaluating how well a biomarker can predict treatment response with survival data. Pharmaceutical Statistics, 2020, 19, 410-423.	1.3	O
7	Metaâ€analysis of clinical trials with competing timeâ€ŧoâ€event endpoints. Biometrical Journal, 2020, 62, 712-723.	1.0	1
8	Authors' response. Statistics in Medicine, 2020, 39, 2692-2692.	1.6	1
9	Genetic markers and phosphoprotein forms of beta-catenin $p\hat{l}^2$ -Cat552 and $p\hat{l}^2$ -Cat675 are prognostic biomarkers of cervical cancer. EBioMedicine, 2020, 61, 103049.	6.1	10
10	A covariateâ€specific timeâ€dependent receiver operating characteristic curve for correlated survival data. Statistics in Medicine, 2020, 39, 2477-2489.	1.6	1
11	Fermat's Passage. Epidemiology, 2020, 31, e47-e47.	2.7	0
12	ipcwswitch: An R package for inverse probability of censoring weighting with an application to switches in clinical trials. Computers in Biology and Medicine, 2019, 111, 103339.	7.0	22
13	Circulating Tumor Cells in Early Breast Cancer. JNCI Cancer Spectrum, 2019, 3, pkz026.	2.9	63
14	Comparative Analysis of Durable Responses on Immune Checkpoint Inhibitors Versus Other Systemic Therapies: A Pooled Analysis of Phase III Trials. JCO Precision Oncology, 2019, 3, 1-10.	3.0	51
15	A Note on the Measurement of Socioeconomic Inequalities in Life Years Lost by Cause of Death. Epidemiology, 2019, 30, 569-572.	2.7	3
16	Circulating Tumor Cells in Breast Cancer Patients Treated by Neoadjuvant Chemotherapy: A Meta-analysis. Journal of the National Cancer Institute, 2018, 110, 560-567.	6.3	206
17	Modeling timeâ€varying exposure using inverse probability of treatment weights. Biometrical Journal, 2018, 60, 323-332.	1.0	9
18	A Joint modelling of socio-professional trajectories and cause-specific mortality. Computational Statistics and Data Analysis, 2018, 119, 39-54.	1.2	1

#	Article	IF	CITATIONS
19	The heart of the matter: years-saved from cardiovascular and cancer deaths in an elite athlete cohort with over a century of follow-up. European Journal of Epidemiology, 2018, 33, 531-543.	5.7	32
20	Access to Heart Transplantation: A Proper Analysis of the Competing Risks of Death and Transplantation Is Required to Optimize Graft Allocation. Transplantation Direct, 2017, 3, e198.	1.6	12
21	Direct Likelihood Inference and Sensitivity Analysis for Competing Risks Regression with Missing Causes of Failure. Biometrics, 2015, 71, 498-507.	1.4	8
22	Relative Index of Inequality and Slope Index of Inequality. Epidemiology, 2015, 26, 518-527.	2.7	149
23	Predictiveness curves in virtual screening. Journal of Cheminformatics, 2015, 7, 52.	6.1	73
24	Learning From Leaders: Life-span Trends in Olympians and Supercentenarians. Journals of Gerontology - Series A Biological Sciences and Medical Sciences, 2015, 70, 944-949.	3.6	27
25	Socioprofessional trajectories and mortality in France, 1976–2002: a longitudinal follow-up of administrative data. Journal of Epidemiology and Community Health, 2015, 69, 339-346.	3.7	11
26	Mortality in Female and Male French Olympians. American Journal of Sports Medicine, 2015, 43, 1505-1512.	4.2	38
27	A competing risks approach for nonparametric estimation of transition probabilities in a non-Markov illness-death model. Lifetime Data Analysis, 2014, 20, 495-513.	0.9	30
28	A competing risks analysis should report results on all cause-specific hazards and cumulative incidence functions. Journal of Clinical Epidemiology, 2013, 66, 648-653.	5.0	339
29	Homebound status increases death risk within two years in the elderly: Results from a national longitudinal survey. Archives of Gerontology and Geriatrics, 2013, 56, 258-264.	3.0	41
30	Regression modeling of the cumulative incidence function with missing causes of failure using pseudoâ€values. Statistics in Medicine, 2013, 32, 3206-3223.	1.6	18
31	Time-Dependent AUC with Right-Censored Data: A Survey. Lecture Notes in Statistics, 2013, , 239-251.	0.2	12
32	Competing risks regression for clustered data. Biostatistics, 2012, 13, 371-383.	1.5	106
33	Testing independence between two sequential gap times in the presence of covariates. Biometrical Journal, 2012, 54, 766-785.	1.0	0
34	A Regression Model for the Conditional Probability of a Competing Event: Application to Monoclonal Gammopathy of Unknown Significance. Journal of the Royal Statistical Society Series C: Applied Statistics, 2011, 60, 135-142.	1.0	7
35	Competing Risks Regression for Stratified Data. Biometrics, 2011, 67, 661-670.	1.4	78
36	Discrimination measures for survival outcomes: Connection between the AUC and the predictiveness curve. Biometrical Journal, 2011, 53, 217-236.	1.0	15

#	Article	IF	CITATION
37	Simulating competing risks data in survival analysis. Statistics in Medicine, 2009, 28, 956-971.	1.6	151
38	Transmission probabilities of HIV and herpes simplex virus type 2, effect of male circumcision and interaction: a longitudinal study in a township of South Africa. Aids, 2009, 23, 377-383.	2.2	33
39	Practical methodology of meta-analysis of individual patient data using a survival outcome. Contemporary Clinical Trials, 2008, 29, 220-230.	1.8	25
40	Competing Events Influence Estimated Survival Probability. Clinical Orthopaedics and Related Research, 2007, 462, 229-233.	1.5	71
41	Robustness of the BYM model in absence of spatial variation in the residuals. International Journal of Health Geographics, 2007, 6, 39.	2.5	11
42	Misspecified regression model for the subdistribution hazard of a competing risk. Statistics in Medicine, 2007, 26, 965-974.	1.6	65
43	Comments on â€~Analysing and interpreting competing risk data' by M. Pintilie,Statistics in Medicine 2006. DOI: 10.1002/sim.2655. Statistics in Medicine, 2007, 26, 3676-3679.	1.6	20
44	Sample size formula for proportional hazards modelling of competing risks. Statistics in Medicine, 2004, 23, 3263-3274.	1.6	84
45	Software to compute and conduct sequential Bayesian phase I or II dose-ranging clinical trials with stopping rules. Computer Methods and Programs in Biomedicine, 2003, 72, 117-125.	4.7	34
46	Host defense and inflammatory gene polymorphisms are associated with outcomes after HLA-identical sibling bone marrow transplantation. Blood, 2002, 100, 3908-3918.	1.4	184